Latest papers

Evaluation of Ziehl-Neelsen stained faecal smear and ELISA as tools for surveillance of clinical paratuberculosis in cattle in the Netherlands.

Longitudinal study of the distribution of Mycobacterium avium subsp. paratuberculosis in the environment of dairy herds in the Michigan Johne's disease control demonstration herd project.

Benefits of obtaining test-negative Level 4 classification for beef producers in the Voluntary Bovine Johne's Disease Control Program.

Candidate gene polymorphisms (BoIFNG, TLR4, SLC11A1) as risk factors for paratuberculosis infection in cattle.

DNA vaccines against mycobacterial diseases.

Preliminary investigation of a humoral and cell-mediated immunity ratio for diagnosis of paratuberculosis in beef cattle.

Early phase morphological lesions and transcriptional responses of bovine ileum infected with Mycobacterium avium subsp. paratuberculosis.

Efficacy of feeding plasma-derived commercial colostrum replacer for the prevention of transmission of Mycobacterium avium subsp paratuberculosis in Holstein calves.

Effect of subcutaneous administration of a killed Mycobacterium avium subsp paratuberculosis vaccine on colonization of tissues following oral exposure to the organism in calves.

In utero Mycobacterium avium subspecies paratuberculosis infection of a pygmy goat.

Limitations of single tests in the diagnosis of MAP.

Johne's disease commonly diagnosed in cattle in south-west Scotland.

Mycobacterium avium paratuberculosis invades human small-intestinal goblet cells and elicits inflammation.

Risk haplotype analysis for bovine paratuberculosis.

Mycobacterium avium subspecies paratuberculosis and its relationship with Crohn's disease.

A questionnaire-based cross-sectional study of clinical Johne's disease on dairy farms in New Zealand.

Time to the occurrence of a decline in milk production in cows with various paratuberculosis antibody profiles.

[Antibiosis instead of the scalpel: new findings for Crohn disease]

Analysis of correlations between the occurrence of anti-MAP antibodies in blood serum and the presence of DNA-MAP in milk.

Therapeutic vaccine comprising Mycobacterium HSP70.